ConductScience.org, home

Paper42908554PubMed

LASSO-based nomogram to predict early treatment failure in advanced hepatocellular carcinoma treated with SBRT, lenvatinib, and tislelizumab.

Zhao Y and 5 others. Front Oncol, 2026.

Cite this record

ConductScience Library. LASSO-based nomogram to predict early treatment failure in advanced hepatocellular carcinoma treated with SBRT, lenvatinib, and tislelizumab. Papers, record 42908554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42908554

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
LASSO-based nomogram to predict early treatment failure in advanced hepatocellular carcinoma treated with SBRT, lenvatinib, and tislelizumab.
Journal
Front Oncol
Year
2026
Publication types
Journal Article
Revised in PubMed
2026-10-24

Source PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhao YYingchun
2Wang SSuming
3He LLi
4Shen XXiaoqian
5Zhang MMiaomiao
6Zhang SSujing

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References53

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139747344Application of the Lasso regularisation technique in mitigating overfitting in air quality prediction models.Sci Rep2025https://conductscience.org/library/papers/39747344PubMed
220808728Regularization Paths for Generalized Linear Models via Coordinate Descent.J Stat Softw2010https://conductscience.org/library/papers/20808728PubMed
330596875PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies.Ann Intern Med2019https://conductscience.org/library/papers/30596875PubMed
425569120Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement.BMJ2015https://conductscience.org/library/papers/25569120PubMed
541060708Efficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis.Hepatol Res2026https://conductscience.org/library/papers/41060708PubMed
637843628Sequencing Systemic Therapy in Hepatocellular Carcinoma.Curr Treat Options Oncol2023https://conductscience.org/library/papers/37843628PubMed
741409240
Clinical efficacy of hepatic arterial infusion chemotherapy combined with transhepatic arterial embolization plus lenvatinib and tislelizumab or transarterial chemoembolization combined with lenvatinib plus tislelizumab in the treatment of advanced hepatocellular carcinoma.
Front Oncol2025https://conductscience.org/library/papers/41409240PubMed
820175033Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.Semin Liver Dis2010https://conductscience.org/library/papers/20175033PubMed
928130846AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology2018https://conductscience.org/library/papers/28130846PubMed
1034027864Cyberknife Radiosurgery in Hepatocellular Carcinoma.J Coll Physicians Surg Pak2021https://conductscience.org/library/papers/34027864PubMed
1120010215Assessing the performance of prediction models: a framework for traditional and novel measures.Epidemiology2010https://conductscience.org/library/papers/20010215PubMed
1231954495Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.J Hepatol2020https://conductscience.org/library/papers/31954495PubMed
1337047482Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment.Int J Mol Sci2023https://conductscience.org/library/papers/37047482PubMed
1436435358Healthcare Costs for Medicare Patients With Hepatocellular Carcinoma in the United States.Clin Gastroenterol Hepatol2023https://conductscience.org/library/papers/36435358PubMed
1535799264Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.J Hematol Oncol2022https://conductscience.org/library/papers/35799264PubMed
1639211358Regularized regression can improve estimates of multivariate selection in the face of multicollinearity and limited data.Evol Lett2024https://conductscience.org/library/papers/39211358PubMed
1717099194Decision curve analysis: a novel method for evaluating prediction models.Med Decis Making2006https://conductscience.org/library/papers/17099194PubMed
1833538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
1925271081Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma.Clin Cancer Res2014https://conductscience.org/library/papers/25271081PubMed
2038363984Using stepwise regression to address multicollinearity is not appropriate.Int J Surg2024https://conductscience.org/library/papers/38363984PubMed

See all 53 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42908554

GET https://conductscience.org/api/papers/v1/42908554/references?page=2